Literature DB >> 33322544

The Significance of Tau Aggregates in the Human Brain.

Rudy J Castellani1,2.   

Abstract

Neurofibrillary degeneration has attracted the attention of neuroscientists as both a hallmark of the disease and a subject for experimentation for more than a century. Recent studies implicate phosphorylated tau (p-tau) directly in neurodegenerative disease pathogenesis, although the human data continue to raise questions. P-tau accumulates with age in a roughly hierarchical manner, but avoids abundance in the neocortex unless co-occurring with amyloid-β. Neurodegenerative tauopathies tend to have p-tau morphologies that differ from aging and Alzheimer's disease. Tau isoforms (3R vs. 4R) have a tendency to vary with tauopathy phenotype for unknown reasons. Selective vulnerability to p-tau and spatial-temporal disconnect from amyloid-β are evident in aging. P-tau assessment at autopsy involves tissue decomposition, which may skew microanatomical observations toward limited biological meaning. Two major consensus guidelines for interpreting p-tau at autopsy emphasize the challenges of clinicopathologic correlation, and reinforce the observation that regional neurodegeneration is a better correlate of clinical signs than is proteinopathy. Despite the proliferation of interesting and novel theories related to tau-mediated pathogenesis, the weight of the human observations suggests that neurofibrillary degeneration is an epiphenomenal hallmark of aging and disease rather than an epicenter of neurotoxicity. This is consistent with numerous tau-targeted therapeutic strategies that have been unsuccessful to date.

Entities:  

Keywords:  Alzheimer’s disease; neurofibrillary; tau; tauopathy

Year:  2020        PMID: 33322544      PMCID: PMC7763851          DOI: 10.3390/brainsci10120972

Source DB:  PubMed          Journal:  Brain Sci        ISSN: 2076-3425


  76 in total

Review 1.  Noradrenergic locus coeruleus neurons: their distant connections and their relationship to neighboring (including cholinergic and GABAergic) neurons of the central gray and reticular formation.

Authors:  B E Jones
Journal:  Prog Brain Res       Date:  1991       Impact factor: 2.453

2.  Tau Prion Strains Dictate Patterns of Cell Pathology, Progression Rate, and Regional Vulnerability In Vivo.

Authors:  Sarah K Kaufman; David W Sanders; Talitha L Thomas; Allison J Ruchinskas; Jaime Vaquer-Alicea; Apurwa M Sharma; Timothy M Miller; Marc I Diamond
Journal:  Neuron       Date:  2016-10-27       Impact factor: 17.173

3.  4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease.

Authors:  L M Sayre; D A Zelasko; P L Harris; G Perry; R G Salomon; M A Smith
Journal:  J Neurochem       Date:  1997-05       Impact factor: 5.372

4.  Oxidative damage is the earliest event in Alzheimer disease.

Authors:  A Nunomura; G Perry; G Aliev; K Hirai; A Takeda; E K Balraj; P K Jones; H Ghanbari; T Wataya; S Shimohama; S Chiba; C S Atwood; R B Petersen; M A Smith
Journal:  J Neuropathol Exp Neurol       Date:  2001-08       Impact factor: 3.685

5.  Pathological correlations of [F-18]-AV-1451 imaging in non-alzheimer tauopathies.

Authors:  Marta Marquié; Marc D Normandin; Avery C Meltzer; Michael Siao Tick Chong; Nicolas V Andrea; Alejandro Antón-Fernández; William E Klunk; Chester A Mathis; Milos D Ikonomovic; Manik Debnath; Elizabeth A Bien; Charles R Vanderburg; Isabel Costantino; Sara Makaretz; Sarah L DeVos; Derek H Oakley; Stephen N Gomperts; John H Growdon; Kimiko Domoto-Reilly; Diane Lucente; Bradford C Dickerson; Matthew P Frosch; Bradley T Hyman; Keith A Johnson; Teresa Gómez-Isla
Journal:  Ann Neurol       Date:  2017-01       Impact factor: 10.422

6.  Tau suppression in a neurodegenerative mouse model improves memory function.

Authors:  K Santacruz; J Lewis; T Spires; J Paulson; L Kotilinek; M Ingelsson; A Guimaraes; M DeTure; M Ramsden; E McGowan; C Forster; M Yue; J Orne; C Janus; A Mariash; M Kuskowski; B Hyman; M Hutton; K H Ashe
Journal:  Science       Date:  2005-07-15       Impact factor: 47.728

7.  Neuropathology of cognitively normal elderly.

Authors:  D S Knopman; J E Parisi; A Salviati; M Floriach-Robert; B F Boeve; R J Ivnik; G E Smith; D W Dickson; K A Johnson; L E Petersen; W C McDonald; H Braak; R C Petersen
Journal:  J Neuropathol Exp Neurol       Date:  2003-11       Impact factor: 3.685

Review 8.  Neuropathological stageing of Alzheimer-related changes.

Authors:  H Braak; E Braak
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

9.  Argyrophilic Grain Disease: Demographics, Clinical, and Neuropathological Features From a Large Autopsy Study.

Authors:  Roberta Diehl Rodriguez; Claudia Kimie Suemoto; Mariana Molina; Camila Fernandes Nascimento; Renata Elaine Paraizo Leite; Renata Eloah de Lucena Ferretti-Rebustini; José Marcelo Farfel; Helmut Heinsen; Ricardo Nitrini; Kenji Ueda; Carlos Augusto Pasqualucci; Wilson Jacob-Filho; Kristine Yaffe; Lea Tenenholz Grinberg
Journal:  J Neuropathol Exp Neurol       Date:  2016-06-09       Impact factor: 3.685

10.  A novel origin for granulovacuolar degeneration in aging and Alzheimer's disease: parallels to stress granules.

Authors:  Rudy J Castellani; Yashi Gupta; Baiyang Sheng; Sandra L Siedlak; Peggy Lr Harris; Jeff M Coller; George Perry; Hyoung-Gon Lee; Massimo Tabaton; Mark A Smith; Xinglong Wang; Xiongwei Zhu
Journal:  Lab Invest       Date:  2011-10-03       Impact factor: 5.662

View more
  2 in total

1.  Path analysis of biomarkers for cognitive decline in early Parkinson's disease.

Authors:  Dmitri K Gramotnev; Galina Gramotnev; Alexandra Gramotnev; Mathew J Summers
Journal:  PLoS One       Date:  2022-05-13       Impact factor: 3.752

2.  Synaptopathy Mechanisms in ALS Caused by C9orf72 Repeat Expansion.

Authors:  Agnes L Nishimura; Natalia Arias
Journal:  Front Cell Neurosci       Date:  2021-06-01       Impact factor: 5.505

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.